FeesSafety
Pluang+

Erasca reports strong Phase 1 results for ERAS-0015 in KRAS-mutant cancers, plans Phase 3 trials in 2027.

Company Fundamentals
20 Nov 2026, 14:00 WIB
GlobeNewsWire
View Source
Bullish
Erasca reports strong Phase 1 results for ERAS-0015 in KRAS-mutant cancers, plans Phase 3 trials in 2027.

Erasca announced positive Phase 1 data for its pan-RAS molecular glue ERAS-0015, showing notable response rates in heavily pretreated KRAS-mutant pancreatic and lung cancers with good safety. The company plans to start potentially registration-enabling Phase 3 trials in second-line lung cancer and first-line pancreatic cancer in 2027. Early combination data with chemotherapy and immunotherapy support further development, alongside promising Phase 1 results for ERAS-4001, a pan-KRAS inhibitor. These advances position Erasca to expand its RAS-targeting cancer therapies significantly next year.

Erasca Inc. stock trades at USD 13.12 on Pluang as of Nov 20, 2026 19:11 WIB, down 7.74% in one day. The company holds a market cap of $4.99 billion and an enterprise value of $4.39 billion. Trading volume reached 4,782,571 shares, with a typical hold time of 4 days on the platform. This data shows active investor interest despite recent price decline.

More News (ERAS)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App